An observational study in Non-resectable Metastatic Cancer of the Lung, Non-resectable Metastatic Cancer of the Colon and Non-resectable Metastatic Cancer of the Rectosigmoid Junction, sponsored by Centre Hospitalier Universitaire Dijon. Terminated at 1 site in France. Per ClinicalTrials.gov, last updated 2022-04-21.
Sponsored by Centre Hospitalier Universitaire Dijon · Observational
Reflexion on the therapeutic strategies to implement in patients at the end of life is advancing rapidly in France. However, beyond the choices presented to patients, sometimes even the decision to carry on, to limit or to stop treatments is also questioned. This decision is subjective; it is influenced by the patient's representation system (emotions, beliefs, values, practices, etc). In addition, even though he or she is the focus of the decision, the patient is not alone; other actors, accompanying the patient, play an important role in the final decision making. These actors, namely the doctors and close relatives, are also influenced in their decision making. This coexistence of representation systems may interfere with objective indicators that help in decision making (functional, clinical and biological) or with the knowledge acquired by doctors in their training and may complicate the decision-making process.
254 studies on the registry are indexed under Bile Duct Neoplasms; 44 are open to participants now.
This study's enrollment of 36 is below the median of 216 across 42 observational studies indexed under Bile Duct Neoplasms.
Browse Bile Duct Neoplasms studies →Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.
Counted across the registry records on this site, refreshed daily.
hospitalized patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
I- PATIENTS
II- CAREGIVERS
III-DOCTORS
Exclusion Criteria:
I- PATIENTS
II- CAREGIVERS
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Interviews · Other: Questionnaires
Stable patients and intermediate responders to treatments and caregivers
Other: Interviews · Other: Questionnaires
Other: Interviews · Other: Questionnaires
Other: Interviews · Other: Questionnaires
Semi-directed interviews, recorded and transcribed for analysis
economic and psycho-social questionnaires
Number of determinants which are privileged by the patients to choose a treatment
Time frame: through study completion, an average of 18 months
Type of determinants which are privileged by the patients to choose a treatment
Time frame: through study completion, an average of 18 months
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Dijon →